RenovoRx (RNXT) Net Margin (2025 - 2026)

RenovoRx (RNXT) posted Net Margin of 618.47% for Q1 2026, up 58.21% sequentially from 1479.87% in Q4 2025, and up 112011.0% YoY from N/an in Q1 2025.

RenovoRx (RNXT) Net Margin (2025 - 2026) Analysis & Trends

RenovoRx has reported Net Margin for 2 years, with the latest figure at 618.47% in Q1 2026.

Quarterly Net Margin rose 112011.0% year-over-year to 618.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 989.39% (changed N/A YoY) and the FY2025 annual result came in at 2877.11%, up 6166707.0% from the prior year.
Net Margin grew to 618.47% in Q1 2026 per RNXT's latest filing, from 1479.87% in the prior quarter.
Over five years, Net Margin peaked at 618.47% in Q1 2026 and troughed at 1738.58% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	30.23%
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	31.16%
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	-16.51%
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	RenovoRx	59.83 Mn	59.83 Mn	766,000.00	-358.53%

Download Data